| Doshi, Ankur |
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk |
|
|
| Active, not recruiting | 3 | 2749 | Europe, US, RoW | Orforglipron, LY3502970, Insulin Glargine | Eli Lilly and Company | Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease | 09/25 | 01/26 | | |
| Active, not recruiting | 3 | 14013 | Europe, Canada, US, RoW | Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml | Novartis Pharmaceuticals | Primary Prevention of Atherosclerotic Cardiovascular Disease | 04/29 | 04/29 | | |
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease |
|
|
| Recruiting | 2 | 268 | Europe, Canada, Japan, US, RoW | TAK-279, Zasocitinib, Placebo | Takeda | Crohn's Disease | 09/26 | 07/27 | | |
NCT06254950: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis |
|
|
| Recruiting | 2 | 207 | Europe, Canada, Japan, US, RoW | TAK-279, Zasocitinib, Placebo | Takeda | Ulcerative Colitis | 09/26 | 08/27 | | |
NCT05936151: A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes |
|
|
| Recruiting | 2 | 120 | Europe, Canada, US | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Overweight or Obesity, CKD, Type 2 Diabetes | 11/25 | 11/25 | | |
NCT05569005: Effect of Switching From Cigarette Smoking to THS on Disease Progression in Mild to Moderate COPD Subjects With Chronic Bronchitis Symptoms. |
|
|
| Terminated | N/A | 715 | Europe, Japan, US, RoW | THS use, Tobacco Heating System 3.0, Cigarette, Smoking Abstinence | Philip Morris Products S.A. | COPD, Smoking, Tobacco Use | 09/24 | 09/24 | | |
| Simon, Patsy |
| Terminated | 4 | 26 | US | Catasyn™ Advanced Technology Hydrogel and SynePure™ Wound Cleanser, Silver Sulfadiazine, Silvadene Topical Product | J. Peter Rubin, MD, Synedgen, Inc., United States Department of Defense | Superficial Partial Thickness Burn | 12/22 | 12/22 | | |
| Terminated | N/A | 1 | US | NeuraGen 3D Nerve Guide Matrix | Integra LifeSciences Corporation | Digital Nerve Injury | 07/23 | 05/24 | | |
| Rubin, J Peter |
| Terminated | 4 | 26 | US | Catasyn™ Advanced Technology Hydrogel and SynePure™ Wound Cleanser, Silver Sulfadiazine, Silvadene Topical Product | J. Peter Rubin, MD, Synedgen, Inc., United States Department of Defense | Superficial Partial Thickness Burn | 12/22 | 12/22 | | |
NCT04440189: Autologous Adipose-derived Stromal Vascular Fraction for Treatment of Knee Osteoarthritis |
|
|
| Recruiting | N/A | 124 | US | GID SVF-2 Device System | GID BIO, Inc. | Osteoarthritis, Knee | 12/23 | 12/24 | | |
| Jadhav, Ashutosh |
| Completed | 3 | 850 | Europe, Canada, US, RoW | Placebo, Nerinetide, NA-1 | NoNO Inc., University of Calgary | Stroke, Acute | 08/23 | 08/23 | | |
| Completed | N/A | 90 | US | Thermogard XP3, Recanalization only | ZOLL Circulation, Inc., USA | Ischemic Stroke | 05/24 | 05/24 | | |
| Lewandowski, Christopher |
| Recruiting | 3 | 860 | Europe, Canada, Japan, US | Recombinant Activated Factor VII (rFVIIa), NovoSeven, NiaStase, Placebo | Joseph Broderick, MD, Novo Nordisk A/S, National Institute of Neurological Disorders and Stroke (NINDS) | Intracerebral Hemorrhage | 01/28 | 01/28 | | |
NCT04225598: Emergency Department-Initiated Buprenorphine Validation Network Trial |
|
|
| Completed | 2 | 2000 | US | CAM2038, Buprenorphine Sublingual Product | Yale University, National Drug Abuse Treatment Clinical Trials Network, The Emmes Company, LLC, Harvard Medical School (HMS and HSDM), University of Pennsylvania, NYU Langone Health, Icahn School of Medicine at Mount Sinai, Alameda Health System, Weill Medical College of Cornell University, National Institute on Drug Abuse (NIDA) | Opioid-use Disorder | 12/24 | 12/24 | | |
| Shirley, Eleanor |
| Terminated | 4 | 26 | US | Catasyn™ Advanced Technology Hydrogel and SynePure™ Wound Cleanser, Silver Sulfadiazine, Silvadene Topical Product | J. Peter Rubin, MD, Synedgen, Inc., United States Department of Defense | Superficial Partial Thickness Burn | 12/22 | 12/22 | | |
NCT04440189: Autologous Adipose-derived Stromal Vascular Fraction for Treatment of Knee Osteoarthritis |
|
|
| Recruiting | N/A | 124 | US | GID SVF-2 Device System | GID BIO, Inc. | Osteoarthritis, Knee | 12/23 | 12/24 | | |
| Ziembicki, Jenny |
| Terminated | 4 | 26 | US | Catasyn™ Advanced Technology Hydrogel and SynePure™ Wound Cleanser, Silver Sulfadiazine, Silvadene Topical Product | J. Peter Rubin, MD, Synedgen, Inc., United States Department of Defense | Superficial Partial Thickness Burn | 12/22 | 12/22 | | |
| Corcos, Alain |
| Terminated | 4 | 26 | US | Catasyn™ Advanced Technology Hydrogel and SynePure™ Wound Cleanser, Silver Sulfadiazine, Silvadene Topical Product | J. Peter Rubin, MD, Synedgen, Inc., United States Department of Defense | Superficial Partial Thickness Burn | 12/22 | 12/22 | | |
| Elias, Garth |
| Terminated | 4 | 26 | US | Catasyn™ Advanced Technology Hydrogel and SynePure™ Wound Cleanser, Silver Sulfadiazine, Silvadene Topical Product | J. Peter Rubin, MD, Synedgen, Inc., United States Department of Defense | Superficial Partial Thickness Burn | 12/22 | 12/22 | | |
| Parsons, Rebecca |
| Terminated | 4 | 26 | US | Catasyn™ Advanced Technology Hydrogel and SynePure™ Wound Cleanser, Silver Sulfadiazine, Silvadene Topical Product | J. Peter Rubin, MD, Synedgen, Inc., United States Department of Defense | Superficial Partial Thickness Burn | 12/22 | 12/22 | | |
| Egro, Francesco |
| Terminated | 4 | 26 | US | Catasyn™ Advanced Technology Hydrogel and SynePure™ Wound Cleanser, Silver Sulfadiazine, Silvadene Topical Product | J. Peter Rubin, MD, Synedgen, Inc., United States Department of Defense | Superficial Partial Thickness Burn | 12/22 | 12/22 | | |
